Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 4/20 | 0.54 |
| ▸ | GRIA4 | P48058 | 13/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.40 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ADH1B | P00325 | 1/20 | 0.36 |
| ▸ | ADH1C | P00326 | 1/20 | 0.36 |
| ▸ | ADH1A | P07327 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8909346 | 0.81 | GRIA1 (0.41) | GRIA1GRIA4CA12CA7CA9 | |
| SCHEMBL22002855 | 0.79 | GRIA1 (0.50) | GRIA1GRIA4GRIA2GRIA3 | |
| SCHEMBL13594561 | 0.79 | GRIA1 (0.50) | GRIA1GRIA4GRIA2GRIA3 | |
| SCHEMBL14769579 | 0.79 | CA12 (0.37) | GRIA1GRIA4CA12CA7CA9 | |
| SCHEMBL13610004 | 0.77 | GRIA1 (0.75) | GRIA1GRIA4GRIA2GRIA3 | |
| SCHEMBL12898957 | 0.75 | GRIA4 (0.47) | GRIA1GRIA4GRIA2GRIA3 | |
| SCHEMBL91255 | 0.74 | — | — | |
| SCHEMBL777408 | 0.74 | — | — | |
| SCHEMBL18198023 | 0.74 | GRIA1 (0.62) | GRIA1GRIA4ALDH1A1 | |
| SCHEMBL12884416 | 0.74 | GRIA4 (0.46) | GRIA1GRIA4GRIA2GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2023-11-21 | — | — | US | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | ITALFARMACO SPA (IT) | 2023-09-14 | — | — | US | disclosed |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| WO-2023147597-A2 | ALLOSTERIC STING MODULATORS AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-03 | — | — | WO | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| WO-2023016525-A1 | COMPOUND AS ATR KINASE INHIBITOR | 苏州爱科百发生物医药技术有限公司 | 2023-02-16 | — | — | WO | disclosed |
| WO-2022120354-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022120353-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-06-09 | — | — | WO | disclosed |
| US-20140275175-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20120071512-A1 | 5-PYRIDIN-3-YL-1, 3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| US-8067415-B2 | Compounds useful as antagonists of CCR2 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067457-B2 | Compounds useful as antagonists of CCR2 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20100234343-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7705158-B2 | Inhibitors of ion channels | ICAGEN, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20090197884-A1 | Compounds Useful as Antagonists of CCR2 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| US-20090163497-A1 | Compounds Useful as Antagonists of CCR2 | MILLENNIUM PHARMACEUTICALS, INC. | 2009-06-25 | — | — | US | disclosed |
| US-20070135493-A1 | INHIBITORS OF ION CHANNELS | ICAGEN (US) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234343-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | GRIA1 477/4885GRIA4 288/4885GRIA2 331/4885 |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | GRIA1 4045/4885GRIA4 3596/4885GRIA2 4345/4885 |
| US-20140275175-A1 | ORGANIC COMPOUNDS | CYP11B2, CYP11B1, SLCO1B1 | GRIA1 3012/4885GRIA4 3487/4885GRIA2 3793/4885 |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | GRIA1 4470/4885GRIA4 4191/4885GRIA2 4426/4885 |
| US-20090197884-A1 | Compounds Useful as Antagonists of CCR2 | CCR2, CCR1, CXCR3 | GRIA1 511/4885GRIA4 1235/4885GRIA2 1009/4885 |
| US-20090163497-A1 | Compounds Useful as Antagonists of CCR2 | CCR2, CCR1, CXCR3 | GRIA1 588/4885GRIA4 1233/4885GRIA2 1121/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | GRIA1 4470/4885GRIA4 4191/4885GRIA2 4426/4885 |
| US-20120071512-A1 | 5-PYRIDIN-3-YL-1, 3-DIHYDRO-INDOL-2-ON DERIVATIVES AND THEIR USE AS MODULATORS OF ALDOSTERONE SYNTHASE AND/OR CYP11B1 | CYP11B1, HSD11B1, CYP11B2 | GRIA1 1609/4885GRIA4 3221/4885GRIA2 2589/4885 |
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | HDAC6, HDAC1, HDAC3 | GRIA1 1437/4885GRIA4 2360/4885GRIA2 1719/4885 |
| US-20070135493-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | GRIA1 477/4885GRIA4 288/4885GRIA2 331/4885 |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | MC2R, REN, CYP11B2 | GRIA1 3562/4885GRIA4 3629/4885GRIA2 4083/4885 |
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | GRIA1 2199/4885GRIA4 1506/4885GRIA2 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.